Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Depriving women of this drug is good public health

Patricia Bencivenga and Adriane Fugh-Berman, MD
Meds
November 19, 2022
Share
Tweet
Share

It’s a public health win that on October 19th, an FDA Advisory Committee voted 14-1 to remove Makena, a drug intended to prevent preterm birth, from the market. The FDA usually follows the advice of its advisory committee, and the briefing documents it supplied the committee make it clear that the agency wants the drug off the market. As well it should. Makena doesn’t work.

After a preliminary trial showed that women assigned to Makena had fewer preterm births than women assigned to placebo, the FDA granted “accelerated approval” to the drug – a temporary, conditional approval designed to speed promising therapies to the public while definitive studies on patient benefits are being done. In this case, the larger, carefully designed follow-up study was designed to see if babies were born healthier, not just later. The study found no benefits to babies, and Makena also showed no benefit over placebo in preventing preterm birth.

That should have been the end of the story — but no. Even after an FDA advisory committee voted 9 to 7 to remove the drug in 2019, the manufacturer fought back, necessitating an unusual second advisory committee meeting.

Public comments at the recent meeting supporting the drug struck three common themes: Preterm birth is a large problem, especially among Black women; Makena is the only FDA-approved therapy, and keeping Makena on the market is important to avoid racial inequities in health care.

It’s certainly true that Black women are at higher risk for preterm birth. Makena won’t help, though; the drug didn’t work in the full population or any sub-group, including Black women. It’s true – but a bit misleading – to say that Makena is the only approved therapy on the market. It was approved conditionally, with the understanding that it could be withdrawn if a confirmatory trial didn’t show benefit.

What is patently not true is that removing Makena from the market disadvantages Black women. Stopping access to a drug that doesn’t work is good public health and exactly what the FDA is supposed to do.

The similarities in the arguments of the groups that testified to keep Makena available were not coincidental. The National Consumers League, Healthy Women, Sidelines, and Miracle Babies, and Dr. Hugh Miller of the WOMB foundation (apparently a contract research organization) all accepted support from at least one of Makena’s manufacturers. The Preterm Birth Prevention Alliance, a project of the National Consumers League, was started by Covis, Makena’s current manufacturer. All of these groups, unsurprisingly, testified to keep Makena on the market.

All representatives from these industry-funded groups ignored the overwhelming evidence that Makena doesn’t work to prevent preterm birth. Every day that the drug is on the market means more profits for Covis. Makena costs more than $700 per weekly injection; Medicaid spends hundreds of millions of dollars a year on the drug – a truly stunning sum to pay for a repackaged drug; the original version has been around for 70 years.

Taxpayers have been on the hook for an expensive drug that doesn’t work since Makena was approved in 2011. Enough is enough. Consumer groups that support ineffective, expensive drugs represent the interests of corporations, not patients. If these groups cared about women and babies, they would support effective prevention measures rather than shilling for an ineffective and expensive drug. We need more comparative research on therapies supported by randomized controlled trials, including cervical cerclage (a surgical procedure), vaginal progesterone, and fish oil, and need more research on the effect of midwifery care and screening for lower genital tract infections.

Makena is a branded version of an old drug, and it doesn’t improve birth outcomes. The committee vote is a resounding and deserved rejection. No one needs a drug that doesn’t work.

Patricia Bencivenga is a special projects coordinator and Adriane Fugh-Berman is a professor of pharmacology and physiology.

Image credit: Shutterstock.com

Prev

Political creep: government intrusion in health care

November 19, 2022 Kevin 10
…
Next

We’re confusing resilience with grit [PODCAST]

November 19, 2022 Kevin 0
…

ADVERTISEMENT

Tagged as: OB/GYN

Post navigation

< Previous Post
Political creep: government intrusion in health care
Next Post >
We’re confusing resilience with grit [PODCAST]

ADVERTISEMENT

Related Posts

  • Low income is a neglected public health issue

    Vania Silva
  • Why working at polling locations is good public health

    Rob Palmer, Isaac Freedman, and Josh Hyman
  • Our public health efforts depend on flexibility and trust

    John Connolly
  • The public health solution to gun deaths

    Nancy Dodson, MD, MPH, Jeffrey Oestreicher, MD and Nina Agrawal, MD
  • Are negative news cycles and social media injurious to our health?

    Rabia Jalal, MD
  • The public health emergency brought health care into the 21st century. Let’s keep moving forward.

    Stephen Parodi, MD

More in Meds

  • FDA delays could end vital treatment for rare disease patients

    GJ van Londen, MD
  • Pharmacists are key to expanding Medicaid access to digital therapeutics

    Amanda Matter
  • How medicine repurposing enables value-based pain management and insomnia therapy

    Olumuyiwa Bamgbade, MD
  • Forced voicemail and diagnosis codes are endangering patient access to medications

    Arthur Lazarus, MD, MBA
  • From stigma to science: Rethinking the U.S. drug scheduling system

    Artin Asadipooya
  • How drugmakers manipulate your health from diagnosis to prescription

    Martha Rosenberg
  • Most Popular

  • Past Week

    • Who gets to be well in America: Immigrant health is on the line

      Joshua Vasquez, MD | Policy
    • Why specialist pain clinics and addiction treatment services require strong primary care

      Olumuyiwa Bamgbade, MD | Conditions
    • Harassment and overreach are driving physicians to quit

      Olumuyiwa Bamgbade, MD | Physician
    • Why peer support can save lives in high-pressure medical careers

      Maire Daugharty, MD | Conditions
    • When a medical office sublease turns into a legal nightmare

      Ralph Messo, DO | Physician
    • Addressing menstrual health inequities in adolescents

      Callia Georgoulis | Conditions
  • Past 6 Months

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Who gets to be well in America: Immigrant health is on the line

      Joshua Vasquez, MD | Policy
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
  • Recent Posts

    • The shocking risk every smart student faces when applying to medical school

      Curtis G. Graham, MD | Physician
    • Clinical ghosts and why they haunt our exam rooms

      Kara Wada, MD | Conditions
    • High blood pressure’s hidden impact on kidney health in older adults

      Edmond Kubi Appiah, MPH | Conditions
    • Deep transcranial magnetic stimulation for depression [PODCAST]

      The Podcast by KevinMD | Podcast
    • How declining MMR vaccination rates put future generations at risk

      Ambika Sharma, Onyi Oligbo, and Katrina Green, MD | Conditions
    • The physician who turned burnout into a mission for change

      Jessie Mahoney, MD | Physician

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

Leave a Comment

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Who gets to be well in America: Immigrant health is on the line

      Joshua Vasquez, MD | Policy
    • Why specialist pain clinics and addiction treatment services require strong primary care

      Olumuyiwa Bamgbade, MD | Conditions
    • Harassment and overreach are driving physicians to quit

      Olumuyiwa Bamgbade, MD | Physician
    • Why peer support can save lives in high-pressure medical careers

      Maire Daugharty, MD | Conditions
    • When a medical office sublease turns into a legal nightmare

      Ralph Messo, DO | Physician
    • Addressing menstrual health inequities in adolescents

      Callia Georgoulis | Conditions
  • Past 6 Months

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Who gets to be well in America: Immigrant health is on the line

      Joshua Vasquez, MD | Policy
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
  • Recent Posts

    • The shocking risk every smart student faces when applying to medical school

      Curtis G. Graham, MD | Physician
    • Clinical ghosts and why they haunt our exam rooms

      Kara Wada, MD | Conditions
    • High blood pressure’s hidden impact on kidney health in older adults

      Edmond Kubi Appiah, MPH | Conditions
    • Deep transcranial magnetic stimulation for depression [PODCAST]

      The Podcast by KevinMD | Podcast
    • How declining MMR vaccination rates put future generations at risk

      Ambika Sharma, Onyi Oligbo, and Katrina Green, MD | Conditions
    • The physician who turned burnout into a mission for change

      Jessie Mahoney, MD | Physician

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Leave a Comment

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...